查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年心律失常監測設備的全球市場
市場調查報告書
商品編碼
1217636

2023-2030 年心律失常監測設備的全球市場

Global Cardiac Arrhythmia Monitoring Devices Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

心律失常監測是一種用於確定不規則心率或心律的原因或類型的測試。 心律失常監測設備是用來監測和監測心率的設備。 開發了許多用於監測心律的產品，例如 Holter 監測器、移動心臟遙測和 ECG 設備。

市場動態

推動全球心律失常監測設備市場的主要因素是，由於心血管疾病的發病率不斷增加，需要持續監測以獲得更好的治療，因此對智能心臟監測設備的需求不斷增長；導致意識激增和新產品發布的技術進步.

智能心臟監護儀新興市場的開發以及對遠程心髒病學不斷增長的需求預計將推動市場增長。

心律失常監測設備市場受到遠程心髒病學需求增加、技術進步不斷增加、老年人口不斷增加、研發投資激增、慢性心髒病數量增加以及新興市場醫療保健基礎設施不斷改善的推動。使用最新技術改進產品。

心律失常監測設備廣泛用於持續監測心律和適當管理醫療狀況。 隨著這些設備越來越受歡迎，政府的承諾和資金也越來越多。 這些資金將用於生產更先進的產品，例如用於監測的智能心臟監護儀和智能手錶。 由於患有心血管疾病的人數不斷增加，這些心律失常監測設備的市場在全球範圍內不斷擴大。 此外，預計主要參與者提供的技術先進的產品也將在市場增長中發揮重要作用。

與這些心律失常監測設備相關的各種新產品發布、研究和提高認識活動正在促進市場的增長。 例如，2021 年 5 月 24 日，專注於推進心臟護理的數字醫療解決方案公司 iRhythm Technologies, Inc. 宣布了兩項新的 510(k) 許可。 一個是具有更好設計的新旗艦顯示器，另一個是改進的人工智能 (AI) 功能。 新的 Zio 監視器的開發旨在提高患者的舒適度，增強的 AI 功能可進一步提高心跳和節律的診斷準確性。

不確定的報銷政策預計會阻礙市場增長。

然而，與這些心臟監測設備相關的不確定報銷政策可能是阻礙市場增長的關鍵因素。 由於這種不確定性，臨床醫生和患者都對採用這些監測設備猶豫不決。

此外，關於批准這些用於監測心血管疾病和醫療狀況的設備的嚴格規則和法規也阻礙了心律失常監測設備市場的增長。 智能心臟監護儀和智能手錶等高級監護儀的高成本也可能限制市場增長。

COVID-19 影響分析

疫情對全球金融預期、運營和危機應對策略產生了負面影響。 COVID-19 的爆發嚴重影響了醫療保健行業。 由於 COVID，心律失常監測設備市場遭受了巨大損失。 主要製造商已經啟動了各種研究和臨床試驗。 世界各地正在開展各種舉措、產品發布、合作和合併，以促進市場的增長。 例如，2022 年 7 月 22 日，專注於推進心臟護理的數字醫療保健解決方案公司 iRhythm Technologies, Inc. 將獲得 USFDA 對 Zio Watch 的 ZEUS 系統（Zio ECG Utilization Software）的許可。宣布關於 該系統是與精準醫療公司 Verily 合作開發的。 ZEUS 系統將值得信賴的心律失常服務與深度學習算法相結合。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 增加智能心電圖儀的開發
      • 對遠程心髒病學（遠程心臟診斷）的需求增加
    • 約束因素
      • 贖回政策不明確
    • 商機
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章副產品

  • 動態心電監護儀
  • 心電圖設備
  • 移動心臟遙測
  • 心臟事件監測器
  • 植入式循環記錄儀
  • 補丁監視器
  • 起搏器
  • 心律轉復除顫器

第八章應用

  • 房顫
  • 心動過緩
  • 房性心動過速
  • 室性心動過速
  • 心室顫動
  • 早產
  • 其他

第 9 章最終用戶

  • 醫院
  • 門診手術中心
  • 診斷中心
  • 專科診所

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第12章公司簡介

  • 飛利浦醫療
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • GE Healthcare
  • Medtronic PLC
  • Cardiac Sense
  • BIOTRONIK
  • iRhythm Technologies, Inc.
  • Preventice Solutions（Boston Scientific Corporation）
  • Medi-Lynx Cardiac Monitoring LLC.
  • ACS Diagnostics
  • Abbott

第13章 DataM

簡介目錄
Product Code: DMMD1281

Market Overview

The global cardiac arrhythmia monitoring devices market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).

Cardiac arrhythmia monitoring is a kind of test utilized to determine the cause and type of the irregular heart rates or heart rhythms. The devices utilized to monitor or observe the heart rates are the cardiac arrhythmia monitoring devices. There are numerous products developed for monitoring the heart rhythms including holter monitor, mobile cardiac telemetry or ECG devices.

Market Dynamics

The major factors driving the global cardiac arrhythmia monitoring devices market are the rising demand for smart cardiac monitoring devices owing to increasing incidences of cardiovascular disorders requiring continuous monitoring for better treatment, surging awareness initiatives, advancements in technologies leading to novel product launches.

The increasing development of smart cardiac monitors and rising demand for telecardiology are expected to drive the market's growth.

The cardiac arrhythmia monitoring devices market is driven by increasing demand of telecardiology, rising advancements in technology, an increase in the geriatric population, a surge in research and development investments, an increasing number of chronic cardiovascular diseases and improvements in novel products using the latest technology along with improvements in medical infrastructure in emerging markets.

The cardiac arrhythmia monitoring devices are used widely for continuous monitoring of rhythms of heart for management of the condition properly. The adoption of these devices is increasing, leading to rising government initiatives and funds. These funds will help produce more developed products such as smart cardiac monitors or smart watches for monitoring. The market for these cardiac arrhythmia monitoring devices is increasing worldwide due to the enhanced number of people suffering from cardiovascular disorders. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market's growth.

Various novel product launches, research studies, and rising awareness initiatives related to these cardiac arrhythmia monitoring devices contribute to the market's growth. For instance, in May 24, 2021, iRhythm Technologies, Inc., a company of digital healthcare solutions focused on cardiac care advancement announced two novel 510(k) clearances. One for a novel flagship monitors with better design and second for an improved artificial intelligence (AI) capabilities. The novel Zio monitor is developed to enhance patient comfort while its AI capabilities advancements will further improve beat and rhythm diagnostic accuracy.

Uncertain reimbursement policies are expected to hamper the market's growth.

However uncertain reimbursement policies associated with these cardiac monitoring devices is the key factor which may hamper the market growth. Due to the uncertainty clinicians as well as patients hesitate in adopting these monitoring devices.

The strict rules and regulations for the approval of these devices utilized for monitoring of cardiovascular disorders or conditions is also a factor hindering the growth of the cardiac arrhythmia monitoring devices market. High costs of highly advanced monitors such as smart cardiac monitors or smart watches can also limit the growth of the market.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The cardiac arrhythmia monitoring devices market has experienced huge losses due to COVID. Key manufacturers have started various research and clinical trials. Various initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, July 22, 2022, iRhythm Technologies, Inc., a company of digital healthcare solutions focused on cardiac care advancement announced about receiving clearance for Zio Watch's ZEUS System (Zio ECG Utilization Software) by USFDA. This system is developed in partnership with Verily, a precision health company. ZEUS System combines trusted cardiac arrhythmia service with deep learned algorithms.

Segment Analysis

The holter monitors segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)

The holter monitor segment is the highest market holder in the global cardiac arrhythmia monitoring devices market. The global cardiac arrhythmia monitoring devices market is segmented based on product as holter monitors, ECG devices, mobile cardiac telemetry, cardiac event monitors, implantable loop recorders, patch monitor, pacemaker, cardioverter-defibrillator. The holter monitors segment is the largest market shareholder due to the increasing adoption of these devices globally for monitoring, increasing technological advancements and novel product launches.

Holter monitors are the small and wearable device that records the rhythm of heart. It is utilized to determine or detect irregular heartbeats (arrhythmias) risk. Holter monitors test is usually done if a traditional electrocardiogram is unable to provide sufficient details about the condition of the heart. These monitors can spot irregular heart rhythms that may be missed by ECG. Holter monitoring is non-invasive and painless. The monitor is usually worn for 1 to 2 days in which all the heartbeats are recorded by the device. The sensors and the wires are easy to hide under clothing. The device can be attached to a strap or worn on a belt.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drives the market's growth. For instance, in January 26, 2022, Royal Philips, a health technology company announced about introducing the first at-home, full-service, 12-lead electrocardiogram (ECG) solution that can be utilized in decentralized clinical trials. This clinical-grade solution is the highly advanced patient-centric ECG included within the cardiac monitoring portfolio of Philips, site-based ECGs with leading cloud-based data collection and evaluation services of Philips.

Geographical Analysis

North America holds the largest market share in the global cardiac arrhythmia monitoring devices market.

North America dominates the global cardiac arrhythmia monitoring devices market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively moderate pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of cardiac arrhythmia monitoring devices such as pacemaker, event monitors, ECG devices or holter monitors, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the cardiac arrhythmia monitoring devices market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in February 10, 2021, CardiacSense, a digital health company involved in developing a medical grade watch announced about receiving the CE Mark for its medical grade smart watch device's marketing & sales in the European Union. The certified indications include Heart Rate Variability (HRV) monitoring and detection of Atrial Fibrillation (A-Fib) with spot Electrocardiogram (ECG) and continuous Photoplethysmography (PPG).

Competitive Landscape

The cardiac arrhythmia monitoring devices market is moderately competitive with local and global companies' presence. Philips Healthcare, GE Healthcare, Medtronic PLC, Cardiac Sense, BIOTRONIK, iRhythm Technologies, Inc., Preventice Solutions (Boston Scientific Corporation), Medi-Lynx Cardiac Monitoring, LLC., ACS Diagnostics, Abbott and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in January 21, 2021, Boston Scientific announced about entering into a definitive acquisition agreement with Preventice Solutions, Inc., a company offering a whole portfolio of mobile cardiac health solutions and services, including ambulatory cardiac monitors such as long and short-term Holter monitor, mobile cardiac telemetry and cardiac event monitors.

GE Healthcare

Overview: GE Healthcare is a subsidiary of American multinational conglomerate General Electric Company. The company manufactures and distributes diagnostic imaging agents and radiopharmaceuticals for imaging modalities used in medical imaging procedures.

Product Portfolio:

CARESCAPE B850 monitor: It incorporates technologically advanced features including smart lead fail and four lead arrhythmia analysis facilitated by EK-Pro algorithm of GE Healthcare. The monitor also provide a broad range of basic or advanced clinical parameters such as regional oximetry (rSO2), plethysmography variability index (PVI), Perfusion Index (PI) and total hemoglobin (SpHb).

Key Development: In July 16, 2022, GE Healthcare announced about introducing portrait mobile continuous wireless wearable sensors patient monitoring solution for supporting clinicians in detecting early patient deterioration.

The global cardiac arrhythmia monitoring devices market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing development of smart cardiac monitors
      • 4.1.1.2. Rising demand for telecardiology
    • 4.1.2. Restraints:
      • 4.1.2.1. Uncertain reimbursement policies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Holter Monitor *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 7.3. ECG Devices
  • 7.4. Mobile Cardiac Telemetry
  • 7.5. Cardiac Event Monitors
  • 7.6. Implantable Loop Recorders
  • 7.7. Patch Monitor
  • 7.8. Pacemaker
  • 7.9. Cardioverter-Defibrillator

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Atrial Fibrillation *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 8.3. Bradycardia
  • 8.4. Atrial Tachycardia
  • 8.5. Ventricular Tachycardia
  • 8.6. Ventricular Fibrillation
  • 8.7. Premature Contraction
  • 8.8. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Diagnostic Centers
  • 9.5. Specialty Clinics

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Philips Healthcare *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. GE Healthcare
  • 12.3. Medtronic PLC
  • 12.4. Cardiac Sense
  • 12.5. BIOTRONIK
  • 12.6. iRhythm Technologies, Inc.
  • 12.7. Preventice Solutions (Boston Scientific Corporation)
  • 12.8. Medi-Lynx Cardiac Monitoring LLC.
  • 12.9. ACS Diagnostics
  • 12.10. Abbott

LIST NOT EXHAUSTIVE

13. Global Cardiac Arrhythmia Monitoring Devices Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Medications
  • 13.3. Contact Us